Extracellular Vesicles Heart Failure Chronic Kidney Disease
- Human and mouse models demonstrate that circulating chronic kidney disease (CKD) extracellular vesicles (EVs) carry small, noncoding miRNA that are toxic to the heart and contribute to the...
- The investigators compared plasma EVs from patients with CKD with healthy controls, both in vitro and in vivo, to determine cardiotoxic function.
- Results demonstrated that circulating EVs from patients with CKD are cardiotoxic and can induce apoptosis, impair contractile function, and restrict calcium ions.
“`html
Human and mouse models demonstrate that circulating chronic kidney disease (CKD) extracellular vesicles (EVs) carry small, noncoding miRNA that are toxic to the heart and contribute to the pathogenesis of heart failure (HF) in patients with CKD. When these miRNAs are blocked, heart function can be improved. The insights,garnered from data published by investigators in Circulation,provide a potential avenue for mediating the risk of cardiovascular disease in this patient population.1,2
Why the Kidneys Can “Poison” the Heart of Patients With CKD
The investigators compared plasma EVs from patients with CKD with healthy controls, both in vitro and in vivo, to determine cardiotoxic function. To confirm the results and gain further insights, they utilized a mouse model and instigated HF with reduced cardiac function. A total of 35 patients with stable,moderate,or advanced CKD,plus 18 comparable controls,were included in the analysis.1,2
Results demonstrated that circulating EVs from patients with CKD are cardiotoxic and can induce apoptosis, impair contractile function, and restrict calcium ions. The investigators characterized significant increases in human AC16 (hAC16)-cardiomyocyte (CM) death compared with healthy controls,
Here’s a breakdown of what pharmacists should know about the link between heart failure (HF) and chronic kidney disease (CKD), based on the provided text:
* Increased Risk: Patients with CKD are at a higher risk of developing HF.
* EV-miRNA Connection: Extracellular vesicles (EVs) containing microRNAs (miRNAs) produced by the kidneys can contribute to HF pathogenesis – essentially “poisoning” the heart.
* Early Detection is Key: Identifying CKD patients at risk for HF early is crucial for improved outcomes through timely treatment. There’s hope for biomarkers to detect risk even when HF is subclinical.
* risk Assessment: Pharmacists should utilize risk scores and consider non-customary risk factors (independent of kidney function) to identify at-risk patients.
* Future Role in Clinical Studies: Pharmacists will be important in validating and understanding new biomarkers related to cardiovascular risk in CKD patients,and possibly guiding more intensive treatment strategies.